Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George J Hutton

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Multiple Sclerosis and Related Disorders|May 15, 2024
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)Torge Rempe, Elsa Rodriguez, Aisha Elfasi, et al.
International Journal of MS Care|June 9, 2015
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled TrialRobert Yapundich, Angela Applebee, Francois Bethoux, et al.
Brain : a Journal of Neurology|October 3, 2007
Autologous HSCT for advanced MS: is the glass half-empty or really half-full?Richard A Nash, Olaf Stuve, James D Bowen, et al.
Multiple Sclerosis and Related Disorders|July 20, 2021
Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosisHyunwoo Lee, Kunio Nakamura, Sridar Narayanan, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Neurology|February 3, 2017
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MSRichard A Nash, George J Hutton, Michael K Racke, et al.
JAMA Neurology|December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim reportRichard A Nash, George J Hutton, Michael K Racke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Multiple Sclerosis and Related Disorders|May 15, 2024
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)Torge Rempe, Elsa Rodriguez, Aisha Elfasi, et al.
International Journal of MS Care|June 9, 2015
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled TrialRobert Yapundich, Angela Applebee, Francois Bethoux, et al.
Brain : a Journal of Neurology|October 3, 2007
Autologous HSCT for advanced MS: is the glass half-empty or really half-full?Richard A Nash, Olaf Stuve, James D Bowen, et al.
Multiple Sclerosis and Related Disorders|July 20, 2021
Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosisHyunwoo Lee, Kunio Nakamura, Sridar Narayanan, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Neurology|February 3, 2017
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MSRichard A Nash, George J Hutton, Michael K Racke, et al.
JAMA Neurology|December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim reportRichard A Nash, George J Hutton, Michael K Racke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Pageof 5